Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Toxicology
Erschienen in: Cardiovascular Toxicology 3/2017

10.08.2016

Contrary microRNA Expression Pattern Between Fetal and Adult Cardiac Remodeling: Therapeutic Value for Heart Failure

verfasst von: Hualin Yan, Yifei Li, Chuan Wang, Yi Zhang, Cong Liu, Kaiyu Zhou, Yimin Hua

Erschienen in: Cardiovascular Toxicology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

microRNAs (miRNAs) belong to a class of non-coding RNAs that regulate post-transcriptional gene expression during development and disease. Growing evidence indicates abundant miRNA expression changes and their important role in cardiac hypertrophy and failure. However, the role of miRNAs in fetal cardiac remodeling is little known. Here, we investigated the altered expression of fifteen miRNAs in rat fetal cardiac remodeling compared with adult cardiac remodeling. Among fifteen tested miRNAs, eleven and five miRNAs (miR-199a-5p, miR-214-3p, miR-155-3p, miR-155-5p and miR-499-5p) are significantly differentially expressed in fetal and adult cardiac remodeling, respectively. After comparison of miRNA expression in fetal and adult cardiac remodeling, we find that miRNA expression returns to the fetal level in adult cardiac failure and is activated in advance of the adult level in fetal failure. The current study highlights the contrary expression pattern between fetal and adult cardiac remodeling and that supports a novel potential therapeutic approach to treating heart failure.
Literatur
1.
Gjesdal, O., Bluemke, D. A., & Lima, J. A. (2011). Cardiac remodeling at the population level—Risk factors, screening, and outcomes. Nature Reviews Cardiology, 8(12), 673–685.CrossRefPubMed
2.
Hill, J. A., & Olson, E. N. (2008). Cardiac plasticity. New England Journal of Medicine, 358(13), 1370–1380.CrossRefPubMed
3.
Balasubramanian, S., et al. (2015). Dasatinib attenuates pressure overload induced cardiac fibrosis in a murine transverse aortic constriction model. PLoS One, 10(10), e0140273.CrossRefPubMedPubMedCentral
4.
Greco, C. M., & Condorelli, G. (2015). Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure. Nature Reviews Cardiology, 12(8), 488–497.CrossRefPubMed
5.
Thum, T., & Condorelli, G. (2015). Long noncoding RNAs and microRNAs in cardiovascular pathophysiology. Circulation Research, 116(4), 751–762.CrossRefPubMed
6.
van Rooij, E., et al. (2007). Control of stress-dependent cardiac growth and gene expression by a microRNA. Science, 316(5824), 575–579.CrossRefPubMed
7.
Thakur, V., et al. (2013). Diagnosis and management of fetal heart failure. Canadian Journal of Cardiology, 29(7), 759–767.CrossRefPubMed
8.
Huhta, J. C. (2015). Diagnosis and treatment of foetal heart failure: Foetal echocardiography and foetal hydrops. Cardiology in the Young, 25(Suppl 2), 100–106.CrossRefPubMed
9.
Huhta, J. C., & Paul, J. J. (2010). Doppler in fetal heart failure. Clinical Obstetrics and Gynecology, 53(4), 915–929.CrossRefPubMed
10.
Zhou, K., et al. (2013). Evaluation of therapeutic effect and cytokine change during transplacental Digoxin treatment for fetal heart failure associated with fetal tachycardia, a case-control study. International Journal of Cardiology, 169(4), e62–e64.CrossRefPubMed
11.
Li, Y., et al. (2014). The study of fetal rat model of intra-amniotic isoproterenol injection induced heart dysfunction and phenotypic switch of contractile proteins. BioMed Research International, 2014, 360687.PubMedPubMedCentral
12.
Fang, J., et al. (2015). Antithetical regulation of alpha-myosin heavy chain between fetal and adult heart failure though shuttling of HDAC5 regulating YY-1 function. Cardiovascular Toxicology, 15(2), 147–156.CrossRefPubMed
13.
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols, 4(1), 44–57.CrossRef
14.
Thum, T., et al. (2007). microRNAs in the human heart: A clue to fetal gene reprogramming in heart failure [Erratum appears in Circulation. 2007 Jul 17;116(3):e135]. Circulation, 116(3), 258–267.CrossRefPubMed
15.
Li, Q., et al. (2010). NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. American Journal of Physiology Heart and Circulatory Physiology, 298(5), H1340–H1347.CrossRefPubMedPubMedCentral
16.
Dong, D. L., et al. (2010). Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: A novel mechanism for progressive cardiac hypertrophy. Hypertension, 55(4), 946–952.CrossRefPubMed
17.
Care, A., et al. (2007). microRNA-133 controls cardiac hypertrophy. Nature Medicine, 13(5), 613–618.CrossRefPubMed
18.
Duisters, R. F., et al. (2009). MiR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ Res., 104(2), 170–178. 6p following 178.CrossRefPubMed
19.
Castoldi, G., et al. (2012). MiR-133a regulates collagen 1A1: Potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. Journal of Cellular Physiology, 227(2), 850–856.CrossRefPubMed
20.
Curtis, A. M., et al. (2015). Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1. Proceedings of the National Academy of Sciences, 112(23), 7231–7236.CrossRef
21.
Bao, J. L., & Lin, L. (2014). MiR-155 and miR-148a reduce cardiac injury by inhibiting NF-kappaB pathway during acute viral myocarditis. European Review for Medical and Pharmacological Sciences, 18(16), 2349–2356.PubMed
22.
Seok, H. Y., et al. (2014). Loss of microRNA-155 protects the heart from pathological cardiac hypertrophy. Circulation Research, 114(10), 1585–1595.CrossRefPubMedPubMedCentral
23.
Escobar, T. M., et al. (2014). MiR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression. Immunity, 40(6), 865–879.CrossRefPubMedPubMedCentral
24.
Heymans, S., et al. (2013). Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation, 128(13), 1420–1432.CrossRefPubMed
25.
el Azzouzi, H., et al. (2013). The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation. Cell Metabolism, 18(3), 341–354.CrossRefPubMed
26.
Rane, S., et al. (2009). Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circulation Research, 104(7), 879–886.CrossRefPubMedPubMedCentral
27.
Song, X. W., et al. (2010). microRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. Journal of Cellular Physiology, 225(2), 437–443.CrossRefPubMed
28.
Haghikia, A., et al. (2011). Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: A key role for ubiquitin-conjugating enzymes. European Heart Journal, 32(10), 1287–1297.CrossRefPubMed
29.
da Costa Martins, P. A., et al. (2010). microRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nature Cell Biology, 12(12), 1220–1227.CrossRefPubMed
30.
Sun, M., et al. (2015). microRNA-214 mediates isoproterenol-induced proliferation and collagen synthesis in cardiac fibroblasts. Scientific Reports, 5, 18351.CrossRefPubMedPubMedCentral
31.
Duan, Q., et al. (2015). microRNA regulation of unfolded protein response transcription factor XBP1 in the progression of cardiac hypertrophy and heart failure in vivo. Journal of Translational Medicine, 13, 363.CrossRefPubMedPubMedCentral
32.
Duan, Q., et al. (2015). microRNA-214 is upregulated in heart failure patients and suppresses XBP1-mediated endothelial cells angiogenesis. Journal of Cellular Physiology, 230(8), 1964–1973.CrossRefPubMedPubMedCentral
33.
Yang, T., et al. (2013). microRNA-214 provokes cardiac hypertrophy via repression of EZH2. Biochemical and Biophysical Research Communications, 436(4), 578–584.CrossRefPubMed
34.
35.
Wang, J., et al. (2014). MiR-499 protects cardiomyocytes from H2O 2-induced apoptosis via its effects on Pdcd4 and Pacs2. RNA Biology, 11(4), 339–350.CrossRefPubMedPubMedCentral
36.
Houser, S. R., et al. (2012). Animal models of heart failure: A scientific statement from the American Heart Association. Circulation Research, 111(1), 131–150.CrossRefPubMed
37.
Teerlink, J. R., Pfeffer, J. M., & Pfeffer, M. A. (1994). Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circulation Research, 75(1), 105–113.CrossRefPubMed
38.
Lefkowitz, R. J., Rockman, H. A., & Koch, W. J. (2000). Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation, 101(14), 1634–1637.CrossRefPubMed
39.
Hou, Y., et al. (2012). Beta-adrenoceptor regulates miRNA expression in rat heart. Medical Science Monitor, 18(8), BR309–BR314.PubMedPubMedCentral
40.
Sang, H. Q., et al. (2015). microRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats. Biomedicine and Pharmacotherapy, 71, 185–189.CrossRefPubMed
41.
van Rooij, E., et al. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proceedings of the National Academy of Sciences, 103(48), 18255–18260.CrossRef
42.
43.
Rajabi, M., et al. (2007). Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Failure Reviews, 12(3–4), 331–343.CrossRefPubMed
44.
Razeghi, P., et al. (2001). Metabolic gene expression in fetal and failing human heart. Circulation, 104(24), 2923–2931.CrossRefPubMed
45.
Kinugawa, K., et al. (2001). Signaling pathways responsible for fetal gene induction in the failing human heart: Evidence for altered thyroid hormone receptor gene expression. Circulation, 103(8), 1089–1094.CrossRefPubMed
46.
Taegtmeyer, H., Sen, S., & Vela, D. (2010). Return to the fetal gene program: A suggested metabolic link to gene expression in the heart. Annals of the New York Academy of Sciences, 1188, 191–198.CrossRefPubMedPubMedCentral
47.
van Bilsen, M., et al. (2004). Metabolic remodelling of the failing heart: The cardiac burn-out syndrome? Cardiovascular Research, 61(2), 218–226.CrossRefPubMed
48.
Cheng, L., et al. (2004). Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nature Medicine, 10(11), 1245–1250.CrossRefPubMed
49.
Lee, L., et al. (2005). Metabolic modulation with perhexiline in chronic heart failure: A randomized, controlled trial of short-term use of a novel treatment. Circulation, 112(21), 3280–3288.CrossRefPubMed
50.
Kolwicz, S. C, Jr., et al. (2012). Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circulation Research, 111(6), 728–738.CrossRefPubMedPubMedCentral
Metadaten
Titel
Contrary microRNA Expression Pattern Between Fetal and Adult Cardiac Remodeling: Therapeutic Value for Heart Failure
verfasst von
Hualin Yan
Yifei Li
Chuan Wang
Yi Zhang
Cong Liu
Kaiyu Zhou
Yimin Hua
Publikationsdatum
10.08.2016
Verlag
Springer US
Erschienen in
Cardiovascular Toxicology / Ausgabe 3/2017
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-016-9381-z

Weitere Artikel der Ausgabe 3/2017

Cardiovascular Toxicology 3/2017 Zur Ausgabe

OriginalPaper

H2S Prevents Cyclosporine A-Induced Vasomotor Alteration in Rats

OriginalPaper

Dofetilide in Overdose: A Case Series from Poison Center Data

OriginalPaper

Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs

OriginalPaper

Lipid Emulsion Inhibits Apoptosis Induced by a Toxic Dose of Verapamil via the Delta-Opioid Receptor in H9c2 Rat Cardiomyoblasts

ReviewPaper

Acrolein Can Cause Cardiovascular Disease: A Review

OriginalPaper

Doxorubicin and Liposomal Doxorubicin Differentially Affect Expression of miR-208a and let-7g in Rat Ventricles and Atria